JAZZ — Jazz Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $16.07bn
- $4.27bn
Jazz Pharma falls as lung cancer drug fails late-stage survival goal
Jazz Pharmaceuticals lung cancer drug fails main trial goal (updated)
Brief: Jazz Pharmaceuticals Provides Update On Zepzelca Phase 3 Trial
Jazz Pharma's lung cancer drug fails late-stage trial
U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
U.S. RESEARCH ROUNDUP-ARM Holdings, CDW, Doordash
Ireland's Jazz Pharmaceuticals Q1 revenue beats estimates, reaffirms FY outlook
Brief: Jazz Pharmaceuticals Q1 Adjusted EPS USD 6.34 Vs. IBES Estimate USD 4.57
Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Brief: Jazz Pharmaceuticals Announces FDA Acceptance And Priority Review Of Supplemental Biologics License Application For Ziihera®
Europe Research Roundup: Barclays, Societe Generale, UBS Group
Brief: Pharma Mar Receives Positive Opinion From EMA Recommending Approval Of Zepzelca With Atezolizumab
U.S. RESEARCH ROUNDUP- Carnival, Five Below, McKesson
RCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Ireland's Jazz Pharmaceuticals beats Q4 revenue, profit estimates
Brief: Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.64 Vs. IBES Estimate USD 6.52
Brief: UK's MHRA Approves Zanidatamab For Treatment Of Biliary Tract Cancer
Expects To Meet 2025 Revenue Guidance - SEC Filing